<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="497">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346186</url>
  </required_header>
  <id_info>
    <org_study_id>RegHCOVIDScreening</org_study_id>
    <nct_id>NCT04346186</nct_id>
  </id_info>
  <brief_title>COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff</brief_title>
  <official_title>COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordsjaellands Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mental Health Services in the Capital Region, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During the COVID-19 pandemic several countries have seen a high risk of transmission for
      health care personnel, with some countries having as many 20-25% of nurses and doctors either
      infected or showing symptoms of COVID-19.

      In this prospective cohort study, we will systematically screen all hospital staff in the
      Capital Region of Denmark for IgM and IgG antibodies against SARS-CoV-2 using a point of care
      tests and an Elisa kit.

      Testing will be offered 3 times: In April 2020, Maj 2020 and September 2020. All participants
      will submit a questionnaire regarding exposures, risk factors and symptoms of COVID-19 in
      relation to each testing. Follow-up will be through electronic patient records and national
      registries.

      We will compare the group of health care personnel with data from a control group of healthy
      volunteer blood donors from the Danish Blood Donor Study.

      The aim of the study is to investigate the proportion of hospital staff with SARS-CoV-2
      antibodies during the study period compared to a control group representing the Danish
      population. We will compare the test characteristics of the two methods of testing, a point
      of care test and Elisa.

      Further, we will investigate the extent to which prior immunization or infection is
      protective for future infection with COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive IgM/IgG tests</measure>
    <time_frame>At inclusion</time_frame>
    <description>Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive IgM/IgG tests</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive IgM/IgG tests</measure>
    <time_frame>5 month</time_frame>
    <description>Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the point of care test and Elisa</measure>
    <time_frame>At inclusion</time_frame>
    <description>Comparison of the resultat from the point of care test and with results from Elisa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the point of care test and Elisa</measure>
    <time_frame>1 months</time_frame>
    <description>Comparison of the resultat from the point of care test and with results from Elisa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the point of care test and Elisa</measure>
    <time_frame>5 months</time_frame>
    <description>Comparison of the resultat from the point of care test and with results from Elisa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-infection rate</measure>
    <time_frame>180 days</time_frame>
    <description>Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-infection rate</measure>
    <time_frame>360 days</time_frame>
    <description>Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IgM/IgG positive participants on follow-up test</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IgM/IgG positive participants on follow-up test</measure>
    <time_frame>5 months</time_frame>
    <description>Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Hospital Staff in the Capital Region of Denmark</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer blood donors</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>IgM and IgG diagnostic kits to SARS-CoV-2</intervention_name>
    <description>Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2</description>
    <arm_group_label>Healthy volunteer blood donors</arm_group_label>
    <arm_group_label>Hospital Staff in the Capital Region of Denmark</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Elisa-test for IgM and IgG to SARS-CoV-2</intervention_name>
    <description>Elisa-test for IgM and IgG to SARS-CoV-2</description>
    <arm_group_label>Healthy volunteer blood donors</arm_group_label>
    <arm_group_label>Hospital Staff in the Capital Region of Denmark</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All staff with any form of contact with patients, employed at any hospital in the Capital
        Region of Denmark will be offered to participate at their place of employment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old

          -  Consent to participation

          -  Employed at a Hospital in the Capitial Region of Denmark

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Kasper Iversen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev-Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henning Bundgaard, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Ullum, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Benfield, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne Dam Poulsen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jørgen Rungby, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fredrik Folke, Associate prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akutberedskabet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thea Kølsen Fischer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordsjællands Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ove Andersen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ida Hageman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mental Health Services in the Capital Region, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Region Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>København NV</city>
        <state>Region Hovedstaden</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center Ballerup</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center København</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center Amager</name>
      <address>
        <city>Copenhagen</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center Stolpegaard</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Børne- og Ungdomspsykiatrisk Center</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjaellands Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center Nordsjælland</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center Sankt Hans</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bornholms Hospital</name>
      <address>
        <city>Rønne</city>
        <zip>3700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center Bornholm</name>
      <address>
        <city>Rønne</city>
        <zip>3700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Kasper Iversen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Immunoglobulin M</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

